CONMED
CNMD
#5797
Rank
$1.09 B
Marketcap
$35.36
Share price
5.58%
Change (1 day)
-41.23%
Change (1 year)
Categories

CONMED - 10-Q quarterly report FY


Text size:
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934




For the Quarter Ended March 29, 1996. Commission File Number 0-16093



CONMED CORPORATION
(Exact name of the registrant as specified in its charter)




New York 16-0977505
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)



310 Broad Street, Utica, New York 13501
(Address of principal executive offices) (Zip Code)



(315) 797-8375
(Registrant's telephone number, including area code)



Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [ x ] No [ ]

The number of shares outstanding of registrant's common stock, as of
April 22, 1996 is 14,906,140 shares.
CONMED CORPORATION


TABLE OF CONTENTS
FORM 10-Q


PART I FINANCIAL INFORMATION



Item Number


Item 1. Financial Statements

- Consolidated Statements of Income

- Consolidated Balance Sheets

- Consolidated Statements of Cash Flows

- Notes to Consolidated Financial
Statements




Item 2. Management's Discussion and Analysis
of Financial Condition and Results
of Operations




PART II OTHER INFORMATION



Item 6. Exhibits and Reports on Form 8-K



Signatures



Exhibit Index
Item 1.
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(thousands except per share amounts)
(unaudited)
<TABLE>
<CAPTION>
For the three months ended
--------------------------
March 31, March 29,
1995 1996
-------- --------
<S> <C> <C>
Net sales .......................................... $ 19,753 $ 29,200
-------- --------

Cost and expenses:
Cost of sales .................................... 10,725 15,167
Selling and administrative ....................... 5,338 7,556
Research and development ......................... 664 683
-------- --------

Total operating expenses .................. 16,727 23,406
-------- --------


Income from operations ............................. 3,026 5,794

Interest income (expense), net ..................... (194) (682)
-------- --------

Income before taxes ................................ 2,832 5,112

Provision for income taxes ......................... 992 1,840
-------- --------

Net income ......................................... $ 1,840 $ 3,272
======== ========



Weighted average common shares and equivalents ..... 10,383 12,570
======== ========



Earnings per share ................................. $ .18 $ .26
======== ========

</TABLE>

See notes to consolidated financial statements.
CONMED CORPORATION
CONSOLIDATED BALANCE SHEETS
(in thousands except share amounts)
(unaudited)
<TABLE>
<CAPTION>
December 29, March 29,
1995 1996
-------- --------
<S> <C> <C>
Current assets:
Cash and cash equivalents ............................ $ 1,539 $ 11,549
Accounts receivable, net ............................. 22,649 23,933
Income taxes receivable .............................. 961
Inventories (Note 4) ................................. 20,943 24,243
Deferred income taxes ................................ 2,678 2,678
Prepaid expenses and other current assets ............ 476 513
-------- --------
Total current assets .......................... 49,246 62,916
Property, plant and equipment, net ..................... 19,728 29,127
Deferred income taxes .................................. 2,907 2,907
Covenant not to compete ................................ 1,153 1,043
Goodwill ............................................... 41,438 60,124
Patents, trademarks, and other assets .................. 4,931 6,456
-------- --------
Total assets .................................. $119,403 $162,573
======== ========

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:

Current portion of long-term debt .................... $ 6,000 $ --
Accounts payable ..................................... 2,351 2,932
Income taxes payable ................................. 1,297
Accrued payroll and withholdings ..................... 2,282 3,644
Accrued pension ...................................... 274 467
Other current liabilities ............................ 989 2,885
-------- --------
Total current liabilities ..................... 11,896 11,225
Long-term debt ......................................... 26,340
Accrued pension ........................................ 276 276
Deferred compensation .................................. 868 896
Long-term leases ....................................... 3,521 3,384
Other long-term liabilities ............................ 1,500 1,496
-------- --------
44,401 17,277
-------- --------
</TABLE>
CONMED CORPORATION
CONSOLIDATED BALANCE SHEETS -- Continued
(in thousands except share amounts)
(unaudited)
<TABLE>
<CAPTION>
December 29, March 29,
1995 1996
-------- --------
<S> <C> <C>
Shareholders' equity:
Preferred stock, par value $.01 per share;
authorized 500,000 shares; none outstanding ... -- --
Common stock, par value $.01 per share;
20,000,000 authorized; 11,000,105 and
14,885,090 issued and outstanding in
1995 and 1996, respectively ...................... 110 149
Paid-in capital ...................................... 44,560 111,543
Retained earnings .................................... 30,332 33,604
-------- --------
75,002 145,296
-------- --------
Total liabilities and shareholders' equity .......... $119,403 $162,573
======== ========
</TABLE>




See notes to consolidated financial statements.
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
<TABLE>
<CAPTION>
For the three months ended
--------------------------
March 31, March 29,
1995 1996
-------- --------
<S> <C> <C>
Cash flows from operating activities:
Net income ......................................... $ 1,840 $ 3,272
-------- --------
Adjustments to reconcile net income
to net cash provided by operations:
Depreciation ................................ 641 800
Amortization ................................ 300 631
Increase (decrease) in cash flows
from changes in assets and liabilities
Accounts receivable ................ (299) 1,290
Inventories ........................ (923) (445)
Prepaid expenses and
other current assets ............. (380) 117
Other assets ....................... (68) (1,244)
Accounts payable ................... 346 581
Income taxes payable ............... 896 2,258
Income tax benefit of stock
option exercises ................. -- 1,032
Accrued payroll and withholdings ... (472) 1,362
Accrued pension .................... 139 193
Accrued patent litigation costs .... (1) --
Other current liabilities .......... 379 (1,337)
Deferred compensation and
other long-term liabilities ...... 129 (273)
-------- --------
687 4,965
-------- --------
Net cash provided by operating activities ... 2,527 8,237
-------- --------

Cash flows from investing activities:
Cash used to liquidate liabilities
associated with the Birtcher acquisition ......... (8,282) --
Acquisition of NDM, net of cash acquired ........... -- (30,721)
Acquisition of property, plant, and equipment ...... (1,684) (1,015)
-------- --------
Net cash used by investing activities ....... (9,966) (31,736)
-------- --------
</TABLE>
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS -- Continued
(in thousands)
(unaudited)
<TABLE>
<CAPTION>
For the three months ended
--------------------------
March 31, March 29,
1995 1996
-------- --------
<S> <C> <C>
Cash flows from financing activities:
Proceeds of long term debt ......................... 11,250 32,660
Proceeds from issuance of common stock ............. -- 65,990
Payments on long-term debt and leases .............. (6,471) (65,141)
-------- --------
Net cash provided by financing activities ...... 4,779 33,509
-------- --------
Net increase (decrease) in cash
and cash equivalents ............................... (2,660) 10,010
Cash and cash equivalents at beginning of year ....... 3,615 1,539
-------- --------
Cash and cash equivalents at end of period ........... $ 955 $ 11,549
======== ========

Supplemental disclosures of cash flow information:
Cash paid during the quarter for:
Interest .................................. $ 9 $ 882
Income taxes .............................. 163 124
</TABLE>







See notes to consolidated financial statements.
CONMED CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1 - Consolidation

The consolidated financial statements include the accounts of CONMED
Corporation (the Company), and its subsidiaries. The Company is primarily
engaged in the development, manufacturing and marketing of disposable medical
products and related devices. All significant intercompany accounts and
transactions have been eliminated in consolidation.

Note 2 - Interim financial information

The statements for the three months ended March 31, 1995 and March 29,
1996 are unaudited; in the opinion of the Company such unaudited statements
include all adjustments (which comprise only normal recurring accruals)
necessary for a fair presentation of the results for such periods. The
consolidated financial statements for the year ending December 27, 1996 are
subject to adjustment at the end of the year when they will be audited by
independent accountants. The results of operations for the three months ended
March 31, 1995 and March 29, 1996 are not necessarily indicative of the results
of operations to be expected for any other quarter nor for the year ending
December 27, 1996. The consolidated financial statements and notes thereto
should be read in conjunction with the financial statements and notes for the
years ended December 30, 1994 and December 29, 1995 included in the Company's
Annual Report to the Securities and Exchange Commission on Form 10-K.

Note 3 - Earnings per share

Earnings per share was computed by dividing net income by the weighted
average number of shares of common stock and common stock equivalents
outstanding during the quarter.

Note 4 - Inventories

The components of inventory are as follows (in thousands):
<TABLE>
<CAPTION>
December 29, March 29,
1995 1996
------- -------
<S> <C> <C>
Raw materials .......................... $ 7,209 $ 8,032
Work-in-process ........................ 5,680 5,336
Finished goods ......................... 8,054 10,875
------- -------
Total ......................... $20,943 $24,243
======= =======
</TABLE>
Note 5 - Business Acquisitions

On March 14, 1995, the Company acquired Birtcher Medical Systems, Inc.
("Birtcher") through an exchange of the Company's common stock for all of the
outstanding common and preferred stock of Birtcher. In connection with this
transaction, the Company issued 1,590,000 shares of common stock valued at
$17,750,000 and assumed approximately $3,500,000 of net liabilities.
Accordingly, the results of operations of the acquired business are included in
the consolidated results of the Company from the date of acquisition. The
acquisition was accounted for using the purchase method of accounting. Goodwill
associated with the acquisition is being amortized on a straight-line basis over
a 40 year period.

On May 22, 1995, the Company acquired the business and certain assets
of the Master Medical Corporation ("Master Medical") for a cash purchase price
of approximately $9,500,000 and assumption of $500,000 of liabilities.
Accordingly, the results of operations of the acquired business are included in
the consolidated results of the Company from the date of acquisition. The
acquisition was accounted for using the purchase method of accounting. Goodwill
associated with the acquisition is being amortized on a straight-line basis over
a 15 year period.

On February 23, 1996, the Company acquired the business and certain
assets of New Dimensions in Medicine, Inc. ("NDM") for a cash purchase price of
approximately $31.3 million and the assumption of $2.7 million of liabilities.
Accordingly, the results of operations of the acquired business are included in
the consolidated results of the Company from the date of acquisition. Goodwill
associated with the acquisition is being amortized on a straight line basis over
a 40 year period. The allocation of the purchase price for this acquisition is
based on management's preliminary estimates; it is possible that re-allocations
will be required during the next twelve months as additional information becomes
available. Management does not believe that such re-allocation will have a
material effect on the Company's results of operations or financial position.

On an unaudited pro forma basis, assuming each of the acquisitions had
occurred as of the beginning of the period, the consolidated results of the
Company would have been as follows: (in thousands, except per share amounts):
<TABLE>
<CAPTION>
For the Quarter For the Quarter
Ended March 31, 1995 Ended March 29, 1996
-------------------- --------------------
<S> <C> <C>
Pro forma revenues ........................ $ 32,110 $32,700
======== =======

Pro forma net income ...................... $ 3,215 $ 3,576
======== =======

Pro forma earnings per
common, and common
equivalent shares ...................... $ .27 $ .28
======== =======
</TABLE>
Note 6 - Stock Split and Stock Offering

On October 31, 1995, the Board of Directors of the Company declared a
three-for-two split of the Company's common stock, to be effected in the form of
a stock dividend, payable on November 30, 1995 to shareholders of record on
November 13, 1995. Accordingly, common stock, retained earnings, earnings per
share, the number of shares outstanding, and the weighted average number of
shares and equivalents outstanding, have been restated to retroactively reflect
the split.

On March 20, 1996, the Company completed a public offering of its
common stock whereby 3,000,000 and 850,000 shares of common stock were sold by
the Company and certain shareholders, respectively. The common shares sold by
the shareholders were received upon the exercise of a warrant and options during
the first quarter of 1996. Net proceeds to the Company related to the sale of
3,000,000 shares and exercise of the warrants and option amounted to
approximately $62,500,000 and $3,500,000, respectively. Of the aggregate
proceeds, $65,000,000 was used to eliminate the Company's indebtedness under its
credit agreements.

Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS

Three months ended March 29, 1996 compared to three months ended March 31, 1995

Sales for the quarter ended March 29, 1996 were $29,200,000, an
increase of 47.8% compared to sales of $19,753,000 in the quarter ended March
31, 1995. The increase was substantially a result of the Birtcher, Master
Medical and NDM acquisitions.

Cost of sales also increased to $15,167,000 in the current quarter
compared to the $10,725,000 in the same quarter a year ago as a result of
increased sales volume. The Company's gross margin percentage was 48.1% for the
first quarter of 1996 as compared to 45.7% for the first quarter of 1995 and an
average of 47.8% for the remaining three quarters of 1995. The continued
improvement in gross margin percentage reflects the economies of scale and
manufacturing efficiencies resulting from the completed acquisitions, and the
cost saving resulting from the fourth quarter 1995 move of the Company's ECG
electrode manufacturing facility from Haverhill, Massachusetts to Rome, New
York.

Selling and administrative costs increased to $7,556,000 compared to
$5,338,000 in the first quarter of 1995. This increased dollar amount resulted
primarily from the effects of the acquisitions. As a percentage of sales,
however, selling and administration declined to 25.9% from 27.0% in the prior
comparable period due to economies of scale resulting from the acquisitions of
Birtcher, Master Medical and NDM.

Research and development expense remained substantially the same in the
first quarter of 1996 compared to 1995.
The first quarter of 1996 had interest expense of $682,000  compared to
interest expense of $194,000 in the first quarter of 1995. As discussed under
Liquidity and Capital Resources, maximum borrowings during the first quarter of
1996 were $65,000,000 of which $32,660,000 related to borrowings associated with
the February 23, 1996 acquisition of NDM. All such indebtedness was repaid in
late March 1996 with proceeds from the Company's equity offering. Aggregate
indebtedness at March 31, 1995 was $20,000,000 of which approximately
$11,000,000 was incurred in the first quarter of 1995 to facilitate the Birtcher
acquisition.

The provision for income tax increased in 1996 due to the higher income
before tax.


Liquidity and Capital Resources

Management believes that cash generated from operations, its current
cash resources and funds available under its banking agreement will provide
sufficient liquidity to ensure continued working capital for operations and
funding of capital expenditures in the foreseeable future.

Prior to the equity offering discussed below, the Company's credit
facility consisted of a $65,000,000 secured term loan and secured revolving line
of credit of $15,000,000. In connection with the NDM acquisition on February 23,
1996, the Company borrowed $32,660,000 bringing aggregate borrowings under the
credit facility to $65,000,000. On March 20, 1996, the Company completed an
equity offering of common stock and used $65,000,000 of the proceeds to
eliminate the indebtedness of the Company. Upon the closing of this equity
offering, the Company's credit facility was amended to consist of a $60,000,000
secured revolving line of credit which expires in March 2001. This facility
carries an interest rate of 0.5%-1.25% over LIBOR depending on defined cash flow
performance ratios.
Item 6. Exhibits and Reports on Form 8-K


List of Exhibits


Exhibit No. Description of Instrument
- - ----------- -------------------------

10.1 First Amendment of Credit Agreements dated March 13, 1996

10.2 Amended and Restated Credit Agreement-Revolving Credit Facility dated as
of March 13, 1996

11 Computation of weighted average number of shares of common stock



Reports on Form 8-K

(1) On February 16, 1996, the Company filed a report on Form 8-K which included
the historic financial statements of a business being acquired.

(2) On February 16, 1996 (as amended on February 26, 1996), the Company filed a
report on Form 8-K which included the consolidated financial statements of
the Company for the three years ended December 29, 1995 and the Company's
amended credit agreements.

(3) On March 8, 1996, the Company filed a report on Form 8-K which included pro
forma financial information for a business acquired.
SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.





CONMED CORPORATION
(Registrant)




Date: May 10, 1996





/s/ Robert D. Shallish, Jr.
---------------------------------
Robert D. Shallish, Jr.
Vice President - Finance
(Principal Financial Officer)
Exhibit Index

Exhibit
- - -------
10.1 - First Amendment of Credit Agreements
dated March 13, 1996

10.2 - Amended and Restated Credit Agreement -
Revolving Credit Facility
dated as of March 13, 1996

11 - Computations of weighted average
number of shares of common stock